We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Siemens Healthineers Introduces Autoanalyzer Assay for Monitoring Fentanyl Usage

By LabMedica International staff writers
Posted on 28 Jan 2020
A recently introduced diagnostic test for use on clinical chemistry autoanalyzers measures the levels of the opioid drug fentanyl and its primary metabolite norfentanyl.

Fentanyl is a synthetic opioid similar to morphine, prescribed for patients with chronic pain, post-operative pain, or treatment of breakthrough pain in cancer patients. More...
The [U.S.] Centers for Disease Control and Prevention has described fentanyl as being a synthetic opioid that is 50 times more potent than heroin and 100 times more potent than morphine.

There are two types of fentanyl: pharmaceutical fentanyl is prescribed to manage severe pain in cancer and surgical patients and end-of-life palliative care. Non-pharmaceutical fentanyl, or illicitly manufactured fentanyl, is often mixed with heroin and/or cocaine - with or without the user’s knowledge. Addictive cocktails incorporating illicitly manufactured fentanyl have evolved into the leading cause of drug overdose death.

When consumed, fentanyl is metabolized to norfentanyl and other metabolites. About 90% of the dose is excreted in urine as norfentanyl, while parent fentanyl accounts for less than 7%.

Siemens Healthineers (Erlangen, Germany) is now distributing the ARK Fentanyl Assay, which provides laboratories with a greater window to screen for fentanyl. The ARK Fentanyl Assay is 510(k) approved for diagnostic use by the [U.S.] Food and Drugs Administration and is CE Marked for use in Europe. The assay measures nanogram per milliliter levels of fentanyl and norfentanyl in 23 microliter urine samples and generates results after only seven minutes. It is available for automated clinical chemistry analyzers offered by Siemens Healthineers including on the Atellica Solution, Viva Systems, Dimension and Dimension Vista Systems.

“Fentanyl testing provides necessary clinical information for more effective patient care where a gap currently exists. Adding the ARK Fentanyl Assay to the Atellica Solution menu offers laboratories an extensive drugs-of-abuse testing menu which can be run efficiently on a single instrument,” said Dr. Deepak Nath, president of laboratory diagnostics at Siemens Healthineers. “It also empowers laboratories to help identify exposure and addiction in their communities, and aid clinicians in getting patients on the path to treatment.”

Related Links:
Siemens Healthineers


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Pipette Controller
Sapphire MaxiPette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.